GLP-1 compound for lowering sugar levels

MYPI2026002690A0Undetermined Publication Date: 2025-05-06GAN & LEE PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2026002690
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-06-19
Filing Date
2024-11-06
Publication Date
2025-05-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reduce hyperglycemia in patients with type II diabetes, and oral antidiabetic drugs and insulin treatment are not sufficient to achieve the optimal blood sugar control target.

Method used

By administering GLP-1 compound or a pharmaceutically acceptable salt, amide or ester thereof to a type II diabetic patient, the specific dosage ranges from 0.25 to 100 mg, and the administration frequency and dosage can be adjusted as needed to reduce the occurrence of adverse events in hyperglycemia.

Benefits of technology

It effectively reduces the HbA1c level in patients with type II diabetes, improves blood sugar control, reduces adverse events related to hyperglycemia, and provides a more effective treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2026002690_DRAWING_001
    Figure PI2026002690_DRAWING_001
  • Figure PI2026002690_DRAWING_002
    Figure PI2026002690_DRAWING_002
Patent Text Reader

Abstract

A GLP-1 compound for lowering sugar levels. Figure 1.
Need to check novelty before this filing date? Find Prior Art

Description

GLP-1 compounds for glucose lowering Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to a GLP-1 compound for treating type II diabetes. Background Art

[0002] Diabetes is a metabolic disorder characterized by hyperglycemia. Optimal glycemic control is the treatment goal for patients with type 2 diabetes. Despite the availability of several oral antidiabetic drugs and insulin, a large proportion of patients with type 2 diabetes do not achieve the recommended glycemic control targets. Glucagon-like peptide 1 (GLP-1) and its analogs and derivatives are highly effective in treating both type 1 and type 2 diabetes. Therefore, the development of GLP-1 peptides with superior properties and appropriate dosing and frequency is urgent.

[0003] Summary of the Invention

[0004] The present invention relates to a method for treating type 2 diabetes, comprising administering a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof, wherein the subject has clinical evidence of hyperglycemia; wherein the method reduces the occurrence of hyperglycemic adverse events (MACE).

[0005] The present invention provides a method for treating or preventing metabolic syndrome, comprising administering 0.25-100 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof.

[0006] Preferably, the metabolic syndrome is diabetes;

[0007] Preferably, the diabetes is type II diabetes.

[0008] In some embodiments, the method comprises administering to a subject in need thereof 0.25-100 mg, preferably 0.5-90 mg, preferably 1-80 mg, preferably 1.5-80 mg, preferably 2-80 mg, preferably 1.5-70 mg, preferably 2-70 mg, preferably 2.5-70 mg, preferably 3-70 mg, preferably 1.5-60 mg, preferably 3-60 mg, preferably 3.5-60 mg, preferably 1.5-55 mg, preferably 3-55 mg, preferably 1.5-48 mg, preferably 3-48 mg, preferably 3.5-48 mg, preferably 1.5-36 mg, preferably 3-36 mg, preferably 3.5-36 mg, preferably 1.5-24 mg, preferably 3-24 mg, preferably 3.5-24 mg, preferably 1.5-18 mg, preferably 3-18 mg, preferably 3.5-18 mg, preferably 1.5-12 mg, preferably 1.5-13 mg, preferably 3-12 mg, preferably 3.5-12 mg, preferably 4-60 mg, preferably 5-60 mg, preferably 6-60 mg, preferably 7-60 mg, preferably 8-60 mg, preferably 9-60 mg, preferably 10-60 mg, preferably 11-60 mg, preferably 12-60 mg, preferably 12-48 mg, preferably 12-36 mg, preferably 12-18 mg, preferably 12-24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof.

[0009] In some embodiments, wherein the method comprises administering to a subject in need thereof 0.25-100 mg, preferably 0.5-90 mg, preferably 1.5-80 mg, preferably 1-80 mg, preferably 1.5-70 mg, preferably 2-80 mg, preferably 2-70 mg, preferably 2.5-70 mg, preferably 3-70 mg, preferably 1.5-60 mg, preferably 3-60 mg, preferably 3.5-60 mg, preferably 1.5-55 mg, preferably 3-55 mg, preferably 1.5-48 mg, preferably 3.5-48 mg, preferably 3-48 mg, preferably 1.5-36 mg, preferably 3-36 mg, preferably 3.5-36 mg, preferably 1.5 -24 mg, preferably 3-24 mg, preferably 3.5-24 mg, preferably 1.5-18 mg, preferably 3-18 mg, preferably 3.5-18 mg, preferably 1.5-12 mg, preferably 1.5-13 mg, preferably 3-12 mg, preferably 3.5-12 mg, preferably 4-60 mg, preferably 5-60 mg, preferably 7-60 mg, preferably 8-60 mg, preferably 9-60 mg, preferably 10-60 mg, preferably 11-60 mg, preferably 12-60 mg, preferably 12-48 mg, preferably 12-36 mg, preferably 12-18 mg, preferably 12-24 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof.

[0010] In some embodiments, wherein the method comprises administering to a subject in need thereof a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at the following doses weekly or biweekly: 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 4 9mg, 50mg, 51mg, 52mg, 53mg, 54mg, 55mg, 56mg, 57mg, 58mg, 59mg, 60mg, 61mg, 62mg, 63mg, 64mg, 65mg, 66mg, 67mg, 68mg, 69mg, or 70mg.

[0011] In some embodiments, the method comprises administering a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof once a week or less, preferably once every two weeks or less.

[0012] In some embodiments, wherein the method comprises administering to a subject in need thereof once a week or once every two weeks a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at a dose of 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg g, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg , 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, 51mg, 52mg, 53mg, 54mg, 55mg, 56mg, 57mg, 58mg, 59mg, 60mg, 61mg, 62mg, 63mg, 64mg, 65mg, 66mg, 67mg, 68mg, 69mg, or 70mg.

[0013] In some embodiments, wherein the method comprises administering to a subject in need thereof an ascending dose at a frequency of once per week or once per two weeks during an ascending dose period, and then administering a maintenance dose at a frequency of once per week or once per two weeks during a maintenance dose period, wherein

[0014] The ascending dose period is at least two weeks, preferably about 2-60 weeks, preferably about 2-55 weeks, preferably about 2-50 weeks, preferably about 2-40 weeks, preferably about 2-31 weeks, preferably about 2-30 weeks, preferably about 2-20 weeks, preferably the ascending dose period is about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks , about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks;

[0015] The maintenance dose period is at least two weeks, preferably about 2-60 weeks, preferably about 2-55 weeks, preferably about 2-50 weeks, preferably about 2-40 weeks, preferably about 2-35 weeks, preferably about 2-30 weeks, preferably about 2-20 weeks, preferably the maintenance dose period is about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks , about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks;

[0016] The increasing dose is independently 0.25 mg-70 mg, preferably 1.5 mg-60 mg, preferably 1.5 mg-48 mg, preferably 1.5 mg-36 mg, preferably 1.5 mg-24 mg, preferably 1.5 mg-24 mg, preferably 1.5 mg-18 mg, preferably 1.5 mg-13 mg, preferably 1.5 mg-12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, each time it is administered; preferably, the increasing dose is independently 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2mg, 2.5mg, 3mg, 3.5mg, 4mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 11mg, 12mg, 13mg, 14mg, 15mg, 16mg, 17mg, 18mg, 19mg, 20mg, 21mg, 22mg, 23mg, 24mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, or 70 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof;

[0017] The maintenance dose is 3-70 mg, preferably 6 mg-60 mg, preferably 9 mg-48 mg, preferably 12 mg-48 mg, preferably 12 mg-36 mg, preferably 12 mg-24 mg, preferably 12 mg-18 mg, preferably 13 mg-24 mg, preferably 13 mg-36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; preferably, the maintenance dose is 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, or 70 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof; and

[0018] The maintenance dose is greater than or equal to the incremental dose.

[0019] In some embodiments, wherein the ascending dose period is about 6-31 weeks, 8-31 weeks, preferably about 10-31 weeks, preferably about 10-24 weeks, preferably about 14-20 weeks, preferably about 16-20 weeks, preferably the ascending dose period is about 6 weeks, 8 weeks, 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 30 weeks or about 31 weeks; preferably the ascending dose period is about 10 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, or about 31 weeks;

[0020] The maintenance dose period is about 4 weeks or more, 5 weeks or more, about 12 weeks or more, about 14 weeks or more, about 16 weeks or more, about 18 weeks or more, or about 20 weeks or more; preferably, the maintenance dose period is about 4-36 weeks; preferably, the maintenance dose period is about 4 weeks, about 5 weeks, about 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 22 weeks, about 24 weeks, about 26 weeks, about 28 weeks, about 30 weeks, about 32 weeks, about 34 weeks, or about 36 weeks; preferably, the maintenance dose period is about 4-30 weeks, preferably, the maintenance dose period is about 4 weeks, about 5 weeks, about 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 22 weeks, about 24 weeks, about 26 weeks, or about 30 weeks;

[0021] The increasing dose is independently about 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 9 mg, 11 mg, 12 mg, 13 mg, 15 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at each administration; preferably, the increasing dose is independently 1.5 mg, 3 mg, 6 mg, 9 mg, 12 mg, 18 mg, 24 mg, or 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at each administration, or the increasing dose is independently 1.5 mg, 3 mg, 5 mg, 7 mg, 9 mg, 11 mg, 13 mg or 15 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at each administration;

[0022] The maintenance dose is 6 mg, 12 mg, 13 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof; and

[0023] The maintenance dose is greater than or equal to the incremental dose.

[0024] In some embodiments, the method comprises administering an ascending dose to a subject in need thereof at a frequency of once a week or once every two weeks during an ascending dose period, and then administering a maintenance dose at a frequency of once a week or once every two weeks during a maintenance dose period, wherein

[0025] The ascending dose period is about 8 weeks, 10 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 30 weeks, or about 31 weeks;

[0026] The maintenance dose period is about 4 weeks or more, about 12 weeks or more, about 16 weeks or more, or about 20 weeks or more; preferably, the maintenance dose period is about 4 weeks, about 5 weeks, about 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 22 weeks, about 24 weeks, about 26 weeks, about 28 weeks, about 30 weeks, about 32 weeks, about 34 weeks, or about 36 weeks; preferably, the maintenance dose period is about 4 weeks, about 12 weeks, about 16 weeks, about 20 weeks, about 24 weeks, 26 weeks, 28 weeks, or about 30 weeks;

[0027] The increasing dose is independently 1.5 mg, 3 mg, 5 mg, 6 mg, 7 mg, 9 mg, 11 mg, 12 mg, 13 mg, 15 mg, 18 mg, 24 mg, 30 mg, or 36 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at each administration;

[0028] The maintenance dose is 3 mg, 6 mg, 12 mg, 13 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof; and

[0029] The maintenance dose is greater than or equal to the escalating dose;

[0030] Preferably:

[0031] When the maintenance dose is about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; and 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 20 weeks; or

[0032] When the maintenance dose is about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks, 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; and 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 16 weeks; or

[0033] When the maintenance dose is about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 18 weeks; or

[0034] When the maintenance dose is about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; and 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 28 weeks or 36 weeks; or

[0035] When the maintenance dose is about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; and 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 24 weeks or 32 weeks; or

[0036] When the maintenance dose is about 15, 17, 18, 19, 21, 24 or 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 1 week; 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 2 weeks; 5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 4 weeks; 7 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 4 weeks; 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 4 weeks; 11 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 4 weeks; or administering 13 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 4 weeks; or when the maintenance dose is about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; administering 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; administering 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; administering 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 14 weeks; or

[0037] When the maintenance dose is about 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 48 mg of the compound of formula (I) once every two weeks. , or a pharmaceutically acceptable salt, amide or ester thereof for more than 12 weeks; or when the maintenance dose is about 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; and 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 10 weeks.

[0038] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 0.25-5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0039] After at least one week of administration of the first dose, a second dose of 3-12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks; preferably, after 1, 2, 3 or 4 weeks of administration of the first dose, a second dose of 3-12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks;

[0040] After 2, 3, 4, 5, 6, 7, or 8 weeks of administration of the second dose, a third dose of 6-24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks.

[0041] In some embodiments, after 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks of administration of the third dose, a fourth dose of 9-48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

[0042] In some embodiments, after 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks of administration of the fourth dose, a fifth dose of 12-60 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

[0043] In some embodiments, after 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks of administration of the fifth dose, a sixth dose of 18-72 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

[0044] In some embodiments, after 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks of administration of the sixth dose, a seventh dose of 24-75 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

[0045] In some embodiments, wherein the first dose is 0.5-5 mg, preferably 1-4.5 mg, preferably 1.5-4 mg, preferably 1.5-3.5 mg, preferably 1.5-3.0 mg, preferably 2-3 mg, preferably 1.5 mg or 3 mg;

[0046] In some embodiments, the second dose is 3-12 mg, preferably 3.5-7.5 mg, preferably 4-7 mg, preferably 4.5-6.5 mg, preferably 5-6 mg, preferably 3 mg or 6 mg;

[0047] In some embodiments, the third dose is 6-20 mg, preferably 6-18 mg, preferably 6-12 mg, preferably 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, or 20 mg, preferably 6 mg or 12 mg;

[0048] In some embodiments, the fourth dose is 9-36 mg, preferably 12-36 mg, preferably 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, or 36 mg, preferably 9 mg or 24 mg;

[0049] In some embodiments, the fifth dose is 12-48 mg, preferably 18-48 mg, preferably 18-36 mg, preferably 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg or 48 mg, preferably 12 mg or 36 mg;

[0050] In some embodiments, the sixth dose is 18-60 mg, preferably 24-60 mg, preferably 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, or 60 mg, preferably 18 mg or 48 mg;

[0051] In some embodiments, the seventh dose is 24-70 mg, preferably 24-60 mg, preferably 24-48 mg, preferably 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, or 70 mg, preferably 24 mg or 48 mg.

[0052] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0053] After administering the first dose for 2 weeks, administering a second dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and

[0054] After 4 weeks of administration of the second dose, a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks. Preferably, a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 18 weeks, preferably more than 20 weeks; preferably, a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for 18 weeks.

[0055] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0056] After administering the first dose for 2 weeks, administer a second dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0057] After administering the second dose for 4 weeks, administering a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and

[0058] After 4 weeks of administration of the third dose, a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered at a frequency of once a week or once every two weeks. Preferably, a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered at a frequency of once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 14 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered at a frequency of once a week or once every two weeks for 14 weeks.

[0059] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0060] After administering the first dose for 2 weeks, administer a second dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0061] After administering the second dose for 4 weeks, administering a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and

[0062] After the third dose is administered for 4 weeks, a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; and

[0063] After 4 weeks of administration of the fourth dose, a fifth dose of 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, a fifth dose of 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 10 weeks, preferably more than 12 weeks, preferably more than 14 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a fifth dose of 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for 10 weeks.

[0064] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0065] After administering the first dose for 2 weeks, administer a second dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0066] After administering the second dose for 4 weeks, administer a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0067] After administering the third dose for 4 weeks, administering a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks;

[0068] After administering the fourth dose for 4 weeks, administering a fifth dose of 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks; and

[0069] After 4 weeks of administration of the fifth dose, a sixth dose of 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered at a frequency of once a week or once every two weeks. Preferably, a sixth dose of 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered at a frequency of once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a sixth dose of 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered at a frequency of once a week or once every two weeks for 12 weeks.

[0070] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0071] After administering the first dose for 4 weeks, administer a second dose of 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0072] After administering the second dose for 4 weeks, administer a third dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0073] After administering the third dose for 4 weeks, administer a fourth dose of 9 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;

[0074] After the fourth dose is administered for 4 weeks, a fifth dose of 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; preferably, a fifth dose of 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a fifth dose of 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for 8 weeks; preferably, 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for 28 weeks or more.

[0075] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0076] After administering the first dose for 4 weeks, administer a second dose of 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0077] After administering the second dose for 4 weeks, administer a third dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0078] After administering the third dose for 4 weeks, administer a fourth dose of 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0079] After administering the fourth dose for 4 weeks, administering a fifth dose of 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;

[0080] After the fifth dose is administered for 4 weeks, a sixth dose of 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, the sixth dose of 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, the sixth dose of 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for 4 weeks; preferably, 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for 24 weeks or more.

[0081] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0082] After administering the first dose for 4 weeks, administer a second dose of 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0083] After administering the second dose for 4 weeks, administer a third dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0084] After administering the third dose for 4 weeks, administer a fourth dose of 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0085] After administering the fourth dose for 4 weeks, administering a fifth dose of 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;

[0086] After administering the fifth dose for 4 weeks, administering a sixth dose of 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks;

[0087] After the sixth dose is administered for 4 weeks, a seventh dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; preferably, the seventh dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, the seventh dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for 4 weeks.

[0088] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 0.5-1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or

[0089] After administering the first dose for 1, 2, 3 or 4 weeks, administering a second dose of 1-3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or

[0090] After administering the second dose for 2, 3, 4, 5, 6, 7, or 8 weeks, administering a third dose of 2-6 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof, once a week or once every two weeks; and / or

[0091] After administering the third dose for 2, 3, 4, 5, 6, 7, or 8 weeks, administering a fourth dose of 2.5-9 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof, once a week or once every two weeks; and / or

[0092] After administering the fourth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, administering a fifth dose of 3-12 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or

[0093] After administering the fifth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, administering a sixth dose of 3.5-18 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or

[0094] After administering the sixth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, administering a seventh dose of 4-24 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or

[0095] After administering the seventh dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, an eighth dose of 6-30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

[0096] In some embodiments, wherein the first dose is 0.5-1.5 mg, preferably 0.5 mg, 0.6 mg, 1 mg, 1.2 mg, 1.5 mg, preferably 0.5 mg or 1.5 mg; and / or

[0097] The second dose is 1-3 mg, preferably 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, preferably 1 mg or 3 mg; and / or

[0098] The third dose is 2-6 mg, preferably 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, preferably 5 mg or 6 mg; and / or

[0099] The fourth dose is 2.5-9 mg, preferably 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, preferably 2.5 mg, 7 mg or 9 mg; and / or

[0100] The fifth dose is 3-12 mg, preferably 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, or 12 mg, preferably 3 mg, 9 mg or 12 mg; and / or

[0101] The sixth dose is 3.5-18 mg, preferably 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, or 18 mg, preferably 3.5 mg, 11 mg, or 18 mg; and / or

[0102] The seventh dose is 4-24 mg, preferably 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg or 24 mg, preferably 4 mg, 18 mg or 24 mg.

[0103] In some embodiments, the method comprises administering to a subject in need thereof a first dose of 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0104] After administering the first dose for 2 weeks, administering a second dose of 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0105] After administering the second dose for 4 weeks, administering a third dose of 5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks;

[0106] After the third dose is administered for 4 weeks, a fourth dose of 7 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks;

[0107] After administering the fourth dose for 4 weeks, administering a fifth dose of 9 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks;

[0108] After the fifth dose is administered for 4 weeks, a sixth dose of 11 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; and

[0109] After the sixth dose is administered for 4 weeks, a seventh dose of 13 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

[0110] In some embodiments, the method is characterized in that the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof is administered parenterally, preferably subcutaneously.

[0111] In some embodiments, the method is characterized in that the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered for more than 12 months, preferably more than 16 months, preferably more than 18 months, preferably more than 24 months, preferably more than 28 months, preferably more than 29 months, preferably more than 30 months.

[0112] In some embodiments, the aforementioned method is characterized in that the subject

[0113] With ≥18.5kg / m 2 BMI, preferably 18.5-35 kg / m 2 BMI; and / or

[0114] Have an HbA1c of 7.0%-11%; and / or

[0115] Fasting blood glucose <15mmol / L.

[0116] In some embodiments, in the aforementioned methods, the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof is administered in the form of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients.

[0117] In some embodiments, the aforementioned pharmaceutical composition comprises:

[0118] About 1.5 mg / ml, about 3 mg / ml, about 6 mg / ml, about 12 mg / ml, about 18 mg / ml, about 24 mg / ml, about 36 mg / ml, or about 48 mg / ml of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof; preferably about 3 mg / ml, about 6 mg / ml, about 12 mg / ml, about 18 mg / ml, about 24 mg / ml, about 36 mg / ml, or about 48 mg / ml of a compound of formula (I), or a pharmaceutically acceptable salt, amide, or ester thereof;

[0119] about 5 mg / ml, about 6 mg / ml, about 7 mg / ml, about 8 mg / ml, about 9 mg / ml, or about 10 mg / ml of NaCl, preferably about 7 mg / ml of NaCl;

[0120] about 1 mM, 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, 9 mM, or about 10 mM citric acid;

[0121] about 1.42 mg / ml, about 1.5 mg / ml, about 2 mg / ml, about 2.5 mg / ml, about 3 mg / ml, about 3.5 mg / ml, about 4 mg / ml, or about 4.5 mg / ml of a Na2HPO4 solution, preferably about 1.42 mg / ml of Na2HPO4; and

[0122] The pH of the pharmaceutical composition is about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1, or about 8.2, preferably about 7.3.

[0123] definition

[0124] For a better understanding of the present invention, definitions and explanations of relevant terms are provided below.

[0125] GLP-1 analogs and GLP-1 derivatives

[0126] As used herein, the term "GLP-1 analog" or "GLP-1 analog" refers to a peptide or compound that is a variant of human glucagon-like peptide-1 (GLP-1(7-37)), wherein one or more amino acid residues of GLP-1(7-37) are replaced, and / or one or more amino acid residues are deleted, and / or one or more amino acid residues are added. Specifically, the sequence of GLP-1(7-37) is shown in SEQ ID NO: 1 in the sequence listing. The peptide having the sequence shown in SEQ ID NO: 1 may also be referred to as "native" GLP-1 or "native" GLP-1(7-37).

[0127] In the sequence listing, the first amino acid residue (histidine) of SEQ ID NO: 1 is numbered 1. However, hereinafter, in accordance with established conventions in the art, the histidine residue is numbered 7, and subsequent amino acid residues are numbered accordingly, ending with glycine at position 37. Therefore, generally, the amino acid residue numbering or position numbering of the GLP-1 (7-37) sequence referred to herein is a sequence starting with His at position 7 and ending with Gly at position 37.

[0128] The [Gly8, Arg34]GLP-1-(7-37) peptide is a GLP-1 analog having Gly and Arg at positions corresponding to position 8 and position 34 of GLP-1(7-37) (SEQ ID NO: 1), respectively. The [Arg34]GLP-1-(7-37) peptide is a GLP-1 analog having Arg at a position corresponding to position 34 of GLP-1(7-37) (SEQ ID NO: 1). Specifically, the amino acid sequence of the [Gly8, Arg34]GLP-1-(7-37) peptide is shown in SEQ ID NO: 2 in the sequence listing.

[0129] In the context of a GLP-1 peptide or analog thereof, the term "derivative" as used herein refers to a chemically modified GLP-1 peptide or analog wherein one or more substituents have been covalently attached to the peptide. Substituents may also be referred to as side chains.

[0130] Unless otherwise stated, when reference is made to acylation with a lysine residue, this is understood to be to be carried out with the e-amino group thereof.

[0131] The term "peptide" when applied to, for example, the GLP-1 analogs of the present invention, refers to a compound comprising a series of amino acids interconnected by amide (or peptide) bonds.

[0132] In a specific embodiment, the peptide is largely or predominantly composed of amino acids linked to each other by amide bonds (e.g., at least 50%, 60%, 70%, 80%, or at least 90% by molar mass). In another specific embodiment, the peptide is composed of amino acids linked to each other by peptide bonds.

[0133] Amino acids are molecules containing an amino group and a carboxylic acid group, optionally with one or more additional groups, often called side chains.

[0134] The term "amino acid" includes proteinogenic amino acids (encoded by the genetic code, including natural amino acids and standard amino acids), as well as non-proteinogenic (not found in proteins and / or not encoded in the standard genetic code), and synthetic amino acids. Non-proteinogenic amino acids are moieties that can be incorporated into peptides via peptide bonds, but are not proteinogenic amino acids. Synthetic non-proteinogenic amino acids include amino acids produced by chemical synthesis, i.e., D-isomers of amino acids encoded by the genetic code, such as D-alanine and D-leucine, Aib (α-aminoisobutyric acid), Abu (α-aminobutyric acid), 3-aminomethylbenzoic acid, anthranilic acid, desamino-histidine, β-analogs of amino acids such as β-alanine, D-histidine, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, and homohistidine, etc.

[0135] Non-limiting examples of amino acids not encoded by the genetic code are γ-carboxyglutamate, ornithine, D-alanine, D-glutamine and phosphoserine. Non-limiting examples of synthetic amino acids are the D-isomers of amino acids, such as D-alanine and D-leucine, Aib (α-aminoisobutyric acid), β-alanine and des-amino-histidine (desH, alternative name imidazole propionic acid, abbreviated Imp).

[0136] In the following, all amino acids not indicating the optical isomer are understood to refer to the L-isomer (unless otherwise specified).

[0137] The term "treatment" includes therapeutic treatment, prophylactic treatment, and use in reducing the risk of a subject developing a disease or other risk factors. Treatment includes, but is not limited to, complete cure of the disease, as well as alleviation of symptoms or mitigation of potential risks. BRIEF DESCRIPTION OF THE DRAWINGS

[0138] Figure 1 is a line graph of the change in body weight from baseline (±SE);

[0139] Figure 2 is a line graph of the change in BMI from baseline (±SE);

[0140] Figure 3 is a line graph of the change in waist circumference from baseline (±SE);

[0141] Figure 4 is a line graph of the change in hip circumference from baseline (±SE);

[0142] FIG5 is a line graph showing the change values ​​(±SE) of waist and hip compared with the baseline. DETAILED DESCRIPTION

[0143] The embodiments of the present invention will be described in detail below with reference to the examples, but those skilled in the art will appreciate that the following examples are intended only to illustrate the present invention and should not be construed as limiting the scope of the invention. Where specific conditions are not specified in the examples, the methods were performed according to conventional conditions or the conditions recommended by the manufacturer. Where the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.

[0144] Abbreviations AE: adverse event AESI: adverse event of special interest AUC: area under the drug concentration-time curve ALB: albumin HbA1c: glycosylated hemoglobin GLP-1: glucagon-like peptide-1 BMI: body mass index N: number of subjects

[0145] Example 1

[0146] Preparation of the title compound: N-ε 26-[2-(2-[2-(2-[2-(2-[4-(21-carboxyheneicosanoylamino)-4(S)-carboxybutanoylamino]ethoxy)ethoxy]acetylamino)ethoxy]ethoxy)acetyl][Gly8,Arg34]GLP-1-(7-37) peptide (Compound (I))

[0147] Compound I is a GLP-1 receptor agonist with CAS registration number: 2668298-70-0, and can be prepared by referring to the method described in, for example, WO2021136303A1.

[0148] Example 2 Pharmaceutical composition of compound (I)

[0149] Pharmaceutical composition 1 of compound (I) was prepared: different concentrations of compound (I) (15 mg / 3 ml or 90 mg / 3 ml), 14 mg / ml propylene glycol, 1.42 mg / ml anhydrous disodium hydrogen phosphate, pH 7.3.

[0150] Pharmaceutical composition 2 of compound (I) was prepared: different concentrations of compound (I) (15 mg / 3 ml or 90 mg / 3 ml), 14 mg / ml propylene glycol, 1.42 mg / ml anhydrous disodium hydrogen phosphate, about 5 mM citric acid; pH was 7.3.

[0151] Pharmaceutical composition 3 of compound (I) was prepared: different concentrations of compound (I) (15 mg / 3 ml or 90 mg / 3 ml), 8.25 mg / ml (141.17 mM) sodium chloride, 1.42 mg / ml anhydrous disodium hydrogen phosphate, and about 5 mM citric acid; pH was 7.3.

[0152] Example 3 Hypoglycemic Effect of Compound (I) Injection in Type II Diabetes

[0153] To evaluate the blood glucose control of compound (I) injection after multiple subcutaneous injections in adult patients with T2DM

[0154] A multicenter, randomized, controlled phase II clinical study to evaluate the efficacy and safety of compound (I) injection in Chinese patients with type 2 diabetes. This phase II clinical study aims to evaluate and compare compound (I) injection with semaglutide Blood glucose control after multiple subcutaneous injections of the injection in adult patients with T2DM.

[0155] Test drug, dosage and administration method, batch number:

[0156] Test drug name: Compound (I) injection;

[0157] Specifications: 5mg / ml (15mg / 3ml), 30mg / ml (90mg / 3ml);

[0158] Batch number: P3AI122001, P3AI423002;

[0159] Valid until: October 2024 / April 2025

[0160] Dosage: Subcutaneous injection (equilibrate to room temperature before injection);

[0161] Produced and provided by Gan & Lee Pharmaceutical Co., Ltd.

[0162] Name, dosage, administration method and batch number of control drug:

[0163] Generic name: semaglutide

[0164] Specifications: 1.34mg / ml (2mg / 1.5ml), 1.34mg / ml (4mg / 3ml);

[0165] Batch numbers: 202303BGL1, 202302BHP2, 202211BDL1, 202210BCW2, 202211BEJ1;

[0166] Validity period: 36 months;

[0167] Dosage: Subcutaneous injection (equilibrate to room temperature before injection);

[0168] Produced by Novo Nordisk A / S.

[0169] Research Methodology:

[0170] This Phase II clinical study is a multicenter, randomized, parallel, controlled study conducted in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetic indicators of compound (I) injection in adult patients with T2DM.

[0171] Patients with type 2 diabetes who are newly diagnosed or not receiving standard treatment will be randomly enrolled and treated with the investigational drug alone. Patients with type 2 diabetes who have been treated before will be randomly enrolled and treated with metformin in addition to the investigational drug. Qualified subjects will be randomly assigned to four different treatment groups of compound (I) injection: the compound (I)-12 mg group once every two weeks, the compound (I)-18 mg group once every two weeks, the compound (I)-24 mg group once every two weeks, and the compound (I)-24 mg group once every week, as well as the control group, the semaglutide-1 mg group once a week (hereinafter referred to as the semaglutide group).

[0172] A total of 476 subjects were screened in this study, of whom 272 were successful and 204 were unsuccessful. Of the successful subjects, 54 were assigned to the semaglutide group, 55 to the biweekly Compound (I)-12 mg group, 54 to the biweekly Compound (I)-18 mg group, 55 to the biweekly Compound (I)-24 mg group, and 54 to the weekly Compound (I)-24 mg group. The inclusion and exclusion criteria are described in Table 2.

[0173] As shown in Table 1, Compound (I) injection and semaglutide were administered to the subjects according to the dosing regimen in Table 1.

[0174] Duration of treatment:

[0175] The maximum study duration for each subject in this study is approximately 29 weeks: including a screening period of up to 2 weeks + a treatment period of 24 weeks (8-18 weeks of dose adjustment and 6-16 weeks of stable dose treatment) + a follow-up period of 3 weeks after the end of treatment (safety follow-up 4 weeks after the last dose).

[0176] Table 1. Experimental design: Amount of compound (I) injection or semaglutide administered at different stages of the experiment Note: W stands for week, and W2 / 4 means the second or fourth week.

[0177] Table 2. Subject inclusion and exclusion criteria (eligible subjects should meet all inclusion criteria; for subjects to be excluded, they meet one or more exclusion criteria)

[0178] Statistical methods:

[0179] 1. Analysis Set

[0180] Demographic data and protocol deviation analyses were performed using the intention-to-treat (ITT) analysis set. Baseline characteristics, prior / concurrent medications and non-pharmacological treatments, and efficacy analyses were performed using the full analysis set (FAS). Drug exposure and compliance, as well as safety analyses, were performed using the safety analysis set (SS). PK analyses were performed using the pharmacokinetic analysis set (PKS). Immunogenicity analyses were performed using the immunogenicity analysis set (IS).

[0181] 2. General description of statistical analysis

[0182] All statistical analyses were performed using 9.4 or above. Pharmacokinetic calculations are performed by Data were analyzed using WinNonlin version 8.3.5 or higher. Quantitative data were descriptively analyzed using the number of cases (missing values), mean, standard deviation, median, quartiles (Q1 and Q3), minimum, and maximum. Qualitative data were descriptively analyzed using frequency and percentages, with percentages calculated using the non-missing data in each analysis set as the denominator. Unless otherwise specified, all statistical tests were performed with a two-sided α of 0.05, and differences were considered statistically significant at a p < 0.05.

[0183] 3. Estimated target analysis

[0184] (1) Main estimation method

[0185] Based on the FAS, the primary efficacy endpoint, "change from baseline in HbA1c after 24 weeks of continuous dosing," was quantitatively described by treatment group. A line graph of the HbA1c values ​​at each visit and the change from baseline was plotted for each dose group, along with a bar graph of the change from baseline in HbA1c after 24 weeks of continuous dosing. The primary outcome measure was analyzed using a mixed-effects model for repeated measures (MMRM).

[0186] (2) Sensitivity analysis method

[0187] Missing data were imputed using multiple imputation (MI) based on the FAS, with stratification factors (naive or experienced), baseline HbA1c value, and baseline BMI as covariates. Statistical comparisons between the experimental and control groups were performed using an analysis of covariance model, with stratification factors (naive or experienced), baseline HbA1c value, baseline BMI, relative dose intensity during the titration period, and relative dose intensity during the stable dose treatment period as covariates.

[0188] (3) Supplementary analysis

[0189] Supplementary analyses in different dimensions are used to confirm the robustness of the main estimation target results.

[0190] Experimental results and conclusions

[0191] 1. Distribution of subjects

[0192] A total of 476 subjects were screened for this study, 204 (42.9%) failed screening, and 272 (57.1%) were actually randomized. All randomized subjects received at least one dose. The ITT set included 54 subjects in the semaglutide group, 55 subjects in the 2-weekly Compound (I)-12 mg group, 54 subjects in the 2-weekly Compound (I)-18 mg group, 55 subjects in the 2-weekly Compound (I)-24 mg group, and 54 subjects in the 1-weekly Compound (I)-24 mg group.

[0193] FAS set: 50 cases in the semaglutide group, 55 cases in the 2-weekly compound (I)-12 mg group, 53 cases in the 2-weekly compound (I)-18 mg group, 54 cases in the 2-weekly compound (I)-24 mg group, and 52 cases in the 1-weekly compound (I)-24 mg group.

[0194] PPS set: 40 cases in the semaglutide group, 42 cases in the 2-weekly compound (I)-12 mg group, 37 cases in the 2-weekly compound (I)-24 mg group, 43 cases in the 2-weekly compound (I)-18 mg group, and 33 cases in the 1-weekly compound (I)-24 mg group

[0195] SS group: 54 cases in the semaglutide group, 55 cases in the 2-weekly compound (I)-12 mg group, 53 cases in the 2-weekly compound (I)-18 mg group, 54 cases in the 2-weekly compound (I)-24 mg group, and 54 cases in the 1-weekly compound (I)-24 mg group.

[0196] PKS set: 52 cases (94.5%) in the 2-weekly Compound (I)-12 mg group, 45 cases (83.3%) in the 2-weekly Compound (I)-18 mg group, 43 cases (78.2%) in the 2-weekly Compound (I)-24 mg group, and 44 cases (81.5%) in the 1-weekly Compound (I)-24 mg group.

[0197] IS group: 54 cases (98.2%) in the compound (I)-12 mg group once every 2 weeks, 52 cases (96.3%) in the compound (I)-18 mg group once every 2 weeks, 50 cases (90.9%) in the compound (I)-24 mg group once every 2 weeks, and 51 cases (94.4%) in the compound (I)-24 mg group once every week.

[0198] 2. Demographics and baseline characteristics

[0199] The demographic and baseline characteristics of the subjects in each group were basically balanced and comparable.

[0200] In the FAS, the mean ± SD age (years) of each treatment group was: semaglutide group: 50.5 ± 10.45, compound (I)-12 mg once every 2 weeks group: 50.0 ± 11.08, compound (I)-18 mg once every 2 weeks group: 50.3 ± 9.16, compound (I)-24 mg once every 2 weeks group: 50.0 ± 10.60, compound (I)-24 mg once every 1 week group: 52.4 ± 11.38.

[0201] This study enrolled two categories of type 2 diabetes subjects: treatment-naive / untreated and previously treated. In the FAS, the treatment-naive subjects in each treatment group were: 22 cases (44.0%) in the semaglutide group, 25 cases (45.5%) in the 2-weekly compound (I)-12 mg group, 23 cases (43.4%) in the 2-weekly compound (I)-18 mg group, 25 cases (46.3%) in the 2-weekly compound (I)-24 mg group, and 24 cases (46.2%) in the 1-weekly compound (I)-24 mg group.

[0202] In FAS, the mean ± SD of HbA1c (%) of each treatment group was: semaglutide group: 8.28 ± 0.933, compound (I)-12 mg once every 2 weeks group: 8.56 ± 1.116, compound (I)-18 mg once every 2 weeks group: 8.31 ± 1.017, compound (I)-24 mg once every 2 weeks group: 8.31 ± 0.937, compound (I)-24 mg once every 1 week group: 8.28 ± 1.065.

[0203] In FAS, the mean ± SD of fasting blood glucose (mmol / L) of each treatment group was: semaglutide group: 9.997 ± 2.7071, compound (I)-12 mg once every 2 weeks group: 9.900 ± 2.2167, compound (I)-18 mg once every 2 weeks group: 9.628 ± 1.9879, compound (I)-24 mg once every 2 weeks group: 9.667 ± 2.2204, compound (I)-24 mg once every 1 week group: 10.018 ± 2.5190.

[0204] 3. Effectiveness Results

[0205] HbA1c (%) index

[0206] In FAS, the MMRM analysis results of the changes in HbA1c (%) compared with baseline after 24 weeks of continuous administration are shown in Table 3.

[0207] Table 3 Changes in HbA1c from baseline (MMRM) FAS (N=264) Note: (1) A mixed-effects model for repeated measures was used to analyze the change in HbA1c from baseline after 24 weeks of continuous treatment. Missing data were not imputed in this model, and treatment group, randomization stratification factor (naive, experienced), baseline HbA1c value, relative dose intensity during the titration period, relative dose intensity during the stable dose treatment period, baseline BMI, and treatment group-visit interaction were used as fixed factors.

[0208] In the FAS, the MMRM analysis of the change in HbA1c (%) from baseline after 24 weeks of continuous administration showed the following results: the least squares mean (LSM) for the semaglutide group was -1.6 (95% CI: -1.85, -1.35). The least squares mean (LSM) for the 2-weekly Compound (I)-12 mg group was -1.87 (95% CI: -2.11, -1.63), compared with -0.27 (95% CI: -0.61, -0.08, P = 0.132). The least squares mean for the 2-weekly Compound (I)-18 mg group was -2.28 (95% CI: -2.54, -2.03), compared with -0.68 (95% CI: -1.04, -0.33, P < 0.001). The least squares mean of the Compound (I)-24 mg group administered twice a week was -1.94 (95% CI: -2.19, -1.69), and the experimental group-control group was -0.34 (95% CI: -0.70, 0.02, P = 0.063). The least squares mean of the Compound (I)-24 mg group administered once a week was -2.32 (95% CI: -2.57, -2.06), and the experimental group-control group was -0.72 (95% CI: -1.08, -0.36, P < 0.001). The efficacy of the Compound (I)-18 mg group administered twice a week and the Compound (I)-24 mg group administered once a week was significantly superior to that of the semaglutide control group (P < 0.001).

[0209] As can be seen from Table 3, Compound (I) injection can effectively reduce HbA1c levels at different doses and dosing frequencies. The reduction in each dose group of Compound (I) is greater than that of the semaglutide group. Among them, the efficacy of the Compound (I)-18 mg group once every 2 weeks and the Compound (I)-24 mg group once every week is significantly better than that of the semaglutide group (P < 0.001).

[0210] Table 4 HbA 1c compliance rate after 24 weeks of continuous administration (Exact Clopper-Pearson FAS) (N=264) Note: (1) The exact Clopper-Pearson method of binomial distribution was used to calculate the HbA1c target rate (proportion of patients with <7.0% and <=6.5%) after 24 weeks of continuous administration and its 95% confidence interval.

[0211] As can be seen from Table 4, in terms of HbA1c compliance rate (HbA1c < 7.0% and HbA1c ≤ 6.5%), the compliance rates of the 2-weekly compound (I)-18 mg group, the 2-weekly compound (I)-18 mg group, and the weekly compound (I)-24 mg group all tended to be better than those of the control group.

[0212] Fasting blood glucose, insulin resistance index (HOMA-IR), pancreatic β-cell function (HOMA-β), insulin sensitivity index (ISI) indicators

[0213] The mixed-effects model for repeated measures (MMRM) was used to analyze the changes in fasting blood glucose compared with baseline.

[0214] Table 5 Changes from baseline in fasting blood glucose, insulin resistance index (HOMA-IR), pancreatic β-cell function (HOMA-β), and insulin sensitivity index (ISI) (MMRM FAS) (N=264) Note: (1) A mixed-effects model for repeated measures was used to analyze the changes in fasting blood glucose, insulin, C-peptide, glucagon, and insulin homeostasis model compared with baseline at each visit. Missing data were not imputed in this model, and treatment group, randomization stratification factor (naive, experienced), visit (V5, V7, V9, V11, V13, V14; as categorical variables), baseline HbA1c value, relative dose intensity during titration, relative dose intensity during stable dose treatment, baseline BMI, and treatment group-visit interaction were used as fixed factors.

[0215] As can be seen from Table 5, in terms of fasting blood glucose, insulin resistance index (HOMA-IR), pancreatic β-cell function (HOMA-β), and insulin sensitivity index (ISI), each treatment group showed varying degrees of improvement compared with the baseline, and the change trend of the compound (I)-18 mg group once every 2 weeks was greater than that of the semaglutide group.

[0216] Weight, BMI, waist circumference, and hip circumference indicators

[0217] From the changes in weight, BMI, waist circumference, hip circumference, and waist-hip comparison baseline (MMRM) in Figures 1-5, it can be seen that the weight, BMI, waist circumference, and hip circumference of each treatment group decreased to varying degrees compared with the baseline, and the change trends of the compound (I)-18 mg group taken once every 2 weeks were greater than those of the semaglutide group.

[0218] 7-point SMBG indicator

[0219] A mixed-effects model was used to analyze the changes in AUC / t of 7-point SMBG compared with baseline.

[0220] In the FAS, the change in AUC / t of SMBG (mmol / L) at 7 points after 24 weeks of continuous administration compared with the baseline was: the least square mean of the semaglutide group was -2.78 (95% CI: -3.42, -2.15); with the semaglutide group as the control group, the least square mean of the 2-weekly compound (I)-12 mg group was -3.41 (95% CI: -4.02, -2.80), and the least square mean of the compound (I)-12 mg group and the control group was -0.63 (95% CI: -1.50, 0.25); the least square mean of the 2-weekly compound (I)-18 mg group was -3.41 (95% CI: -4.03, 0.83). , -2.80), and the least square mean of the group and the control group was -0.63 (95% CI: -1.51, 0.25); the least square mean of the 2-weekly compound (I)-24 mg group was -2.51 (95% CI: -3.11, -1.90), and the least square mean of the group and the control group was 0.27 (95% CI: -0.60, 1.15); the least square mean of the 1-weekly compound (I)-24 mg group was -3.47 (95% CI: -4.09, -2.84), and the least square mean of the group and the control group was -0.68 (95% CI: -1.58, 0.21), see Table 6.

[0221] Table 6 Changes in AUC / t of 7-point SMBG from baseline (FAS, N=264)

[0222] After 24 weeks of continuous administration, the AUC / t of SMBG at 7 points (mixed effects model) decreased in all treatment groups compared with the baseline. The decreases in the 2-weekly compound (I)-12 mg group, the 2-weekly compound (I)-18 mg group, and the 1-weekly compound (I)-24 mg group were greater than those in the control group.

[0223] Adverse reactions of compound (I) injection

[0224] Adverse reactions to Compound (I) injection were common with glucagon-like peptide-1 receptor agonists (GLP-1RAs). The most common adverse reactions were nausea, vomiting, decreased appetite, diarrhea, abdominal distension, weakness, and elevated lipase, similar to those seen in the semaglutide group.

[0225] Medication adherence

[0226] In this study, the compliance (actual dosage / prescribed dosage) of the subjects in each treatment group of Compound (I) was 80%-120% for 100% of the subjects. In the semaglutide group, there was 1 subject (1.9%) whose compliance was less than 80%.

[0227] The relative dose intensity (actual dose / planned dose of the dose group) of each treatment group was: semaglutide group: 76.938% (SD: 37.5625), compound (I)-12 mg once every 2 weeks group: 77.096% (SD: 32.5139), compound (I)-18 mg once every 2 weeks group: 56.679% (SD: 38.0158), compound (I)-24 mg once every 2 weeks group: 53.472% (SD: 36.5147), and compound (I)-24 mg once every 1 week group: 54.670% (SD: 36.9173).

[0228] Table 7 Summary of Subject Compliance (SS, N=271) Note: (1) Compliance (%) = (actual dose administered / ordered dose) × 100%. (2) Compliance below 80% or above 120% is defined as poor compliance. (3) Relative dose intensity (%) = (actual dose administered / planned dose for the dose group) × 100%.

[0229] Example 4 Study on the dose titration strategy of compound (I) in type II diabetes

[0230] In the completed clinical trial in Example 3, two titration methods have been explored in the 2-weekly group: V2.0 regimen: the 12mg / 18mg / 24mg group was titrated according to 3mg-6mg-6mg-9mg-9mg-12mg-12mg-18mg-18mg-24mg-24mg; V3.0 regimen: the 12mg / 18mg / 24mg group was titrated according to 3mg-6mg-6mg-12mg-12mg-24mg-24mg.

[0231] Based on the summary incidence of gastrointestinal adverse reactions at the dose of the test drug, the incidence rates of compound (I) in the overall population were 45.6%, 53.7%, 45.6%, 62.8%, 42.0%, and 38.3% at 3 mg, 6 mg, 9 mg, 12 mg, 18 mg, and 24 mg, respectively. When titrating from 3 mg to 12 mg, the incidence of gastrointestinal adverse events increased with increasing dose, while when titrating from 18 mg to 24 mg, the incidence of gastrointestinal adverse events decreased with increasing dose. Furthermore, the incidence rates of gastrointestinal adverse events at 18 mg and 24 mg were lower than those at the starting dose (3 mg). This suggests that the 3 mg to 12 mg dose represents a stage in which subjects establish tolerance. Combined with the above-mentioned dropout results, this suggests that slow titration is more effective in ensuring subject safety.

[0232] The present invention has been described through the above-described embodiments. However, it should be understood that the above-described embodiments are for illustrative and illustrative purposes only and are not intended to limit the present invention to the described embodiments. Furthermore, it will be understood by those skilled in the art that the present invention is not limited to the above-described embodiments and that further variations and modifications may be made based on the teachings of the present invention, all of which fall within the scope of the present invention. The scope of protection of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for treating or preventing metabolic syndrome, the method comprising administering 0.25-100 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof, Preferably, the metabolic syndrome is diabetes; Preferably, the diabetes is type II diabetes.

2. The method according to claim 1, wherein the method comprises administering to a subject in need thereof about 0.25-100 mg, preferably about 0.5-90 mg, preferably about 1-80 mg, preferably about 1.5-80 mg, preferably 2-80 mg, preferably 1.5-70 mg, preferably 2-70 mg, preferably 2.5-70 mg, preferably 3-70 mg, preferably 1.5-60 mg, preferably 3-60 mg, preferably 3.5-60 mg, preferably 1.5-55 mg, preferably 3-55 mg, preferably 1.5-48 mg, preferably 3-48 mg, preferably 3.5-48 mg, preferably 1.5-36 mg, preferably 3-36 mg, preferably 3.5-36 mg, preferably 1.5- 24mg, preferably 3-24mg, preferably 3.5-24mg, preferably 1.5-18mg, preferably 3-18mg, preferably 3.5-18mg, preferably 1.5-12mg, preferably 1.5-13mg, preferably 3-12mg, preferably 3.5-12mg, preferably 4-60mg, preferably 5-60mg, preferably 6-60mg, preferably 7-60mg, preferably 8-60mg, preferably 9-60mg, preferably 10-60mg, preferably 11-60mg, preferably 12-60mg, preferably 12-48mg, preferably 12-36mg, preferably 12-18mg, preferably 12-24mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof.

3. The method according to claim 1 or 2, wherein: The method comprises administering to a subject in need thereof 0.25-100 mg, preferably 0.5-90 mg, preferably 1.5-80 mg, preferably 1-80 mg, preferably 1.5-70 mg, preferably 2-80 mg, preferably 2-70 mg, preferably 2.5-70 mg, preferably 3-70 mg, preferably 1.5-60 mg, preferably 3-60 mg, preferably 3.5-60 mg, preferably 1.5-55 mg, preferably 3-55 mg, preferably 1.5-48 mg, preferably 3.5-48 mg, preferably 3-48 mg, preferably 1.5-36 mg, preferably 3-36 mg, preferably 3.5-36 mg, preferably 1.5-24 mg, preferably 2-36 mg, preferably 2.5-36 mg, preferably 3.5-36 mg, preferably 1.5-24 mg, preferably 2-36 mg, preferably 2.5-36 mg, preferably 2.5-24 mg, preferably 2.5-36 ... Preferably, the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered at a dose of 3-24 mg, preferably 3.5-24 mg, preferably 1.5-18 mg, preferably 3-18 mg, preferably 3.5-18 mg, preferably 1.5-12 mg, preferably 1.5-13 mg, preferably 3-12 mg, preferably 3.5-12 mg, preferably 4-60 mg, preferably 5-60 mg, preferably 7-60 mg, preferably 8-60 mg, preferably 9-60 mg, preferably 10-60 mg, preferably 11-60 mg, preferably 12-60 mg, preferably 12-48 mg, preferably 12-36 mg, preferably 12-18 mg, preferably 12-24 mg.

4. The method according to any one of claims 1 to 3, wherein: The method comprises administering to a subject in need thereof a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at the following doses per week or every two weeks: 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25mg, 26mg, 27mg, 28mg, 29mg, 30mg, 31mg, 32mg, 33mg, 34mg, 35mg, 36mg, 37mg, 38mg, 39mg, 40mg, 41mg, 42mg, 43mg, 44mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, 51mg, 52mg, 53mg, 54mg, 55mg, 56mg, 57mg, 58mg, 59mg, 60mg, 61mg, 62mg, 63mg, 64mg, 65mg, 66mg, 67mg, 68mg, 69mg, or 70mg.

5. The method according to any one of claims 1 to 4, wherein: The method comprises administering a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof once a week or less, preferably once every two weeks or less.

6. The method according to any one of claims 1 to 5, wherein: The method comprises administering to a subject in need thereof once a week or once every two weeks a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, at a dose of 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg 64mg, 65mg, 66mg, 67mg, 68mg, 69mg, or 70mg; preferably, the dose administered each time is independently the same or different.

7. The method according to any one of claims 1 to 6, wherein: The method comprises first administering an ascending dose to a subject in need thereof at a frequency of once a week or once every two weeks during an ascending dose period, and then administering a maintenance dose at a frequency of once a week or once every two weeks during a maintenance dose period, wherein The increasing dose period is at least two weeks, preferably about 2-60 weeks, preferably about 2-55 weeks, preferably about 2-50 weeks, preferably about 2-40 weeks, preferably about 2-31 weeks, preferably about 2-30 weeks, preferably about 2-20 weeks, preferably the increasing dose period is about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks. , about 23 weeks, about 24 weeks, about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks; The maintenance dose period is at least two weeks, preferably about 3 weeks or more, about 4 weeks or more, about 5 weeks or more, about 6 weeks or more, about 7 weeks or more, about 8 weeks or more, about 9 weeks or more, about 10 weeks or more, about 11 weeks or more, about 12 weeks or more, about 13 weeks or more, about 14 weeks or more, about 15 weeks or more, about 16 weeks or more, about 17 weeks or more, about 18 weeks or more, about 19 weeks or more, about 20 weeks or more, about 21 weeks or more, about 22 weeks or more, about 23 weeks or more, about 24 weeks or more, about 25 weeks or more, about 26 weeks or more, about 27 weeks or more, about 28 weeks or more, about 29 weeks or more, about 30 weeks or more, about 31 weeks or more, about 32 weeks or more, about 33 weeks or more, about 34 weeks or more, about 35 weeks or more, about 36 weeks or more, about 37 weeks or more, about 38 weeks or more, about 39 weeks or more, about 40 weeks or more, about 41 weeks or more, About 42 weeks or more, about 43 weeks or more, about 44 weeks or more, about 45 weeks or more, about 46 weeks or more, about 47 weeks or more, about 48 weeks or more, about 49 weeks or more, about 50 weeks or more, about 51 weeks or more, about 52 weeks or more, about 53 weeks or more, about 54 weeks or more, about 55 weeks or more, about 56 weeks or more, about 57 weeks or more, about 58 weeks or more, about 59 weeks or more, or about 60 weeks or more; preferably about 2-120 weeks, preferably about 2-100 weeks, preferably about 2-80 weeks, preferably about 2-70 weeks, preferably about 2-80 weeks. The maintenance dose period is preferably about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks. , about 25 weeks, about 26 weeks, about 27 weeks, about 28 weeks, about 29 weeks, about 30 weeks, about 31 weeks, about 32 weeks, about 33 weeks, about 34 weeks, about 35 weeks, about 36 weeks, about 37 weeks, about 38 weeks, about 39 weeks, about 40 weeks, about 41 weeks, about 42 weeks, about 43 weeks, about 44 weeks, about 45 weeks, about 46 weeks, about 47 weeks, about 48 weeks, about 49 weeks, about 50 weeks, about 51 weeks, about 52 weeks, about 53 weeks, about 54 weeks, about 55 weeks, about 56 weeks, about 57 weeks, about 58 weeks, about 59 weeks, or about 60 weeks; The increasing dose is independently about 0.25mg-70mg, preferably about 1.5mg-60mg, preferably about 1.5mg-48mg, preferably about 1.5mg-36mg, preferably about 1.5mg-24mg, preferably about 1.5mg-24mg, preferably about 1.5mg-18mg, preferably about 1.5mg-13mg, preferably about 1.5mg-12mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, each time it is administered; preferably, the increasing dose is independently about 0.25mg, about 0.5mg, 1mg, about 1.5mg, about 2mg, about 2.5mg, about 3mg, about 3.5mg, about 4mg, about 5mg, about 6mg, about 7mg, about 8mg, about 9mg, 10mg, 11mg, about 12mg, 13mg, 14mg, 15mg, 16 mg, 17 mg, about 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, about 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, about 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, about 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, about 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, or 70 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; The maintenance dose is about 3-70 mg, preferably about 6 mg-60 mg, preferably about 9 mg-48 mg, preferably about 12 mg-48 mg, preferably about 12 mg-36 mg, preferably about 12 mg-24 mg, preferably The maintenance dose is about 12 mg to 18 mg, preferably about 13 mg to 24 mg, preferably about 13 mg to 36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; preferably, the maintenance dose is about 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, about 9 mg, 10 mg, 11 mg, about 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, about 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, about 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg 67mg, 68mg, 69mg, or 70mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; and The maintenance dose is greater than or equal to the incremental dose; Preferably: During the increasing dose period, the administration time of each different increasing dose is independently about 1 week or more, about 2 weeks or more, about 3 weeks or more, about 4 weeks or more, about 5 weeks or more, about 6 weeks or more, about 7 weeks or more, about 8 weeks or more, about 9 weeks or more, about 10 weeks or more, about 11 weeks or more, about 12 weeks or more, about 13 weeks or more, about 14 weeks or more, about 15 weeks or more, about 16 weeks or more, about 17 weeks or more, about 18 weeks or more, about 19 weeks or more, or about 20 weeks or more; preferably, during the increasing dose period, the administration time of each different increasing dose is independently about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 17 weeks, about 18 weeks, about 19 weeks, or about 20 weeks; Preferably: During the increasing dose period, the increasing dose is about 1.1-3 times of the previous different increasing dose, preferably about 1.1-2 times, preferably about 1.1 times, about 1.2 times, about 1.3 times, about 1.4 times, about 1.5 times, about 1.6 times, about 1.7 times, about 1.8 times, about 1.9 times, about 2.1 times, about 2.2 times, about 2.3 times, about 2.4 times, about 2.5 times, about 2.6 times, about 2.7 times, about 2.8 times, about 2.9 times or about 3 times.

8. The method according to claim 7, wherein: The increasing dose period is about 6-31 weeks, 8-31 weeks, preferably about 10-31 weeks, preferably about 10-24 weeks, preferably about 14-20 weeks, preferably about 16-20 weeks, preferably the increasing dose period is about 6 weeks, 8 weeks, 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 30 weeks or about 31 weeks; preferably the increasing dose period is about 10 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, or about 31 weeks; The maintenance dose period is about 4 weeks or more, 5 weeks or more, about 12 weeks or more, about 14 weeks or more, about 16 weeks or more, about 18 weeks or more, about 20 weeks or more, about 30 weeks or more, about 40 weeks or more, about 50 weeks or more, about 60 weeks or more, about 70 weeks or more, about 80 weeks or more, or about 90 weeks or more; Preferably, the maintenance dose period is about 4-36 weeks; preferably, the maintenance dose period is about 4 weeks, about 5 weeks, about 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 22 weeks, about 24 weeks, about 26 weeks, about 28 weeks, about 30 weeks, about 32 weeks, about 34 weeks or about 36 weeks; preferably, the maintenance dose period is about 4-30 weeks, preferably, the maintenance dose period is about 4 weeks, about 5 weeks, about 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 22 weeks, about 24 weeks, about 26 weeks, or about 30 weeks; The increasing dose is about 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 9 mg, 11 mg, 12 mg, 13 mg, 15 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, respectively, at each administration; preferably, the ... The increasing dose is about 1.5 mg, about 3 mg, about 6 mg, about 9 mg, about 12 mg, about 18 mg, about 24 mg, or about 36 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, respectively; or the increasing dose is about 1.5 mg, about 3 mg, about 5 mg, about 7 mg, about 9 mg, about 11 mg, about 13 mg or about 15 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, respectively, at each administration; The maintenance dose is about 6 mg, about 12 mg, about 13 mg, about 18 mg, about 24 mg, about 30 mg, about 36 mg, or about 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; and The maintenance dose is greater than or equal to the incremental dose.

9. The method according to claim 7 or 8, wherein: The method comprises first administering an increasing dose to a subject in need at a frequency of once a week or once every two weeks during an increasing dose period, and then administering a maintenance dose at a frequency of once a week or once every two weeks during a maintenance dose period, wherein, The ascending dose period is about 8 weeks, 10 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 30 weeks, or about 31 weeks; The maintenance dose period is about 4 weeks or more, about 12 weeks or more, about 16 weeks or more, about 20 weeks or more, about 30 weeks or more, about 40 weeks or more, about 50 weeks or more, about 60 weeks or more, about 70 weeks or more, about 80 weeks or more, or about 90 weeks or more; preferably, the maintenance dose period is about 4 weeks, about 5 weeks, about 10 weeks, about 12 weeks, about 14 weeks, about 16 weeks, about 18 weeks, about 20 weeks, about 22 weeks, about 24 weeks, about 26 weeks, about 28 weeks, about 30 weeks, about 32 weeks, about 34 weeks or about 36 weeks; preferably, the maintenance dose period is about 4 weeks, about 12 weeks, about 16 weeks, about 20 weeks, about 24 weeks, 26 weeks, 28 weeks, or about 30 weeks; The increasing dose is independently about 1.5 mg, 3 mg, 5 mg, 6 mg, 7 mg, 9 mg, 11 mg, 12 mg, 13 mg, 15 mg, 18 mg, 24 mg, 30 mg, or 36 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at each administration; The maintenance dose is about 3 mg, 6 mg, 12 mg, 13 mg, 18 mg, 24 mg, 30 mg, 36 mg, or 48 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; and The maintenance dose is greater than or equal to the incremental dose; Preferably: When the maintenance dose is about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks or more than 4 weeks; administering 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks or more than 4 weeks; administering 6 mg of the compound of formula (I) once every two weeks; 9 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than 4 weeks; and 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks or more than 4 weeks; administering 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks or more than 4 weeks; administering 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; administering 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks or more than 4 weeks; administering 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for ... 9 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered at a frequency of more than 4 weeks, 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered at a frequency of once every two weeks for more than 4 weeks; and 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered at a frequency of once every two weeks for more than 16 weeks, preferably more than about 18 weeks, preferably more than about 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks or more than 4 weeks; administering 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; administering 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 18 weeks, preferably more than about 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; or more than about 14 weeks, preferably more than about 16 weeks, preferably more than about 18 weeks, preferably more than about 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 18 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 9 mg of the compound of formula (I), once every two weeks for more than 4 weeks. , or a pharmaceutically acceptable salt, amide or ester thereof for more than 4 weeks, 12 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than 4 weeks; and 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for more than 24 weeks or 32 weeks, preferably more than about 14 weeks, preferably more than about 16 weeks, preferably more than about 18 weeks, preferably more than about 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 15, 17, 18, 19, 21, 24 mg or 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 1.5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 1 week; 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 2 weeks; 5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week for more than 2 weeks; 7 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week for more than 4 weeks; 9 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week for more than 4 weeks; 11 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week for more than 4 weeks; 13 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week for more than 4 weeks; or When the maintenance dose is about 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; or a pharmaceutically acceptable salt, amide or ester thereof for more than 14 weeks, preferably more than about 16 weeks, preferably more than about 18 weeks, preferably more than about 20 weeks, preferably more than about 25 weeks, preferably more than about 30 weeks, preferably about 20-120 weeks, preferably about 20-100 weeks, preferably about 20-80 weeks; preferably about 20-60 weeks; or When the maintenance dose is about 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 48 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 12 weeks; or When the maintenance dose is about 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, the method comprises administering to a subject in need thereof 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 2 weeks; 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; 24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 4 weeks; and 36 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once every two weeks for more than 10 weeks.

10. The method according to any one of claims 1 to 9, wherein: The method comprises administering to a subject in need thereof a first dose of 0.25-5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After at least 1 week of administration of the first dose, a second dose of 3-12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks; preferably, after 1, 2, 3 or 4 weeks of administration of the first dose, a second dose of 3-12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks; After the second dose is administered for 2, 3, 4, 5, 6, 7, or 8 weeks, a third dose of 6-24 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks.

11. The method according to claim 10, wherein: After administering the third dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, a fourth dose of 9-48 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

12. The method according to claim 11, wherein: After administering the fourth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, a fifth dose of 12-60 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

13. The method according to claim 12, wherein: After administering the fifth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, a sixth dose of 18-72 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

14. The method according to claim 13, wherein: After administering the sixth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, a seventh dose of 24-75 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

15. The method according to any one of claims 10 to 14, wherein: The first dose is 0.5-5 mg, preferably 1-4.5 mg, preferably 1.5-4 mg, preferably 1.5-3.5 mg, preferably 1.5-3.0 mg, preferably 2-3 mg, preferably 1.5 mg or 3 mg; and / or The second dose is 3-12 mg, preferably 3.5-7.5 mg, preferably 4-7 mg, preferably 4.5-6.5 mg, preferably 5-6 mg, preferably 3 mg or 6 mg; and / or The third dose is 6-20 mg, preferably 6-18 mg, preferably 6-12 mg, preferably 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, or 20 mg, preferably 6 mg or 12 mg; and / or The fourth dose is 9-36 mg, preferably 12-36 mg, preferably 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, or 36 mg, preferably 9 mg or 24 mg; and / or The fifth dose is 12-48 mg, preferably 18-48 mg, preferably 18-36 mg, preferably 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg or 48 mg, preferably 12 mg or 36 mg; and / or The sixth dose is 18-60 mg, preferably 24-60 mg, preferably 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, or 60 mg, preferably 18 mg or 48 mg; and / or The seventh dose is 24-70 mg, preferably 24-60 mg, preferably 24-48 mg, preferably 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, or 70 mg, preferably 24 mg or 48 mg.

16. The method according to any one of claims 1-6 or 7-9 or 10-15, wherein: The method comprises administering a first dose of 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof at a frequency of once a week or once every two weeks; After administering the first dose for 2 or 4 weeks, administering a second dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and After the second dose is administered for 4 weeks, a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks. Preferably, a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 18 weeks, preferably more than 20 weeks; preferably, a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks for 18 weeks.

17. The method according to any one of claims 1-6, 7-9 or 10-15, wherein: The method comprises administering a first dose of 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof once a week or once every two weeks; After administering the first dose for 2 or 4 weeks, administer a second dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for 4 weeks, administering a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and After the third dose is administered for 4 weeks, a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 14 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for 14 weeks.

18. The method according to any one of claims 1-6, 7-9 or 10-15, wherein: The method comprises administering a first dose of 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof once a week or once every two weeks; After administering the first dose for 2 or 4 weeks, administer a second dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for 4 weeks, administering a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and After the third dose is administered for 4 weeks, a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; and After the fourth dose is administered for 4 weeks, a fifth dose of 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, a fifth dose of 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 10 weeks, preferably more than 12 weeks, preferably more than 14 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a fifth dose of 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for 10 weeks.

19. The method according to any one of claims 1-6, 7-9 or 10-15, wherein: The method comprises administering a first dose of 3 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, to a subject in need thereof at a frequency of once a week or once every two weeks; After administering the first dose for 2 or 4 weeks, administer a second dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for 4 weeks, administer a third dose of 12 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for 4 weeks, administer a fourth dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof at a frequency of once a week or once every two weeks; After the fourth dose is administered for 4 weeks, a fifth dose of 36 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; and After the fifth dose is administered for 4 weeks, a sixth dose of 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks. Preferably, a sixth dose of 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a sixth dose of 48 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for 12 weeks.

20. The method according to any one of claims 1-6, 7-9 or 10-15, wherein: The method comprises administering to a subject in need thereof a first dose of 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for 2 or 4 weeks, administer a second dose of 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for 4 weeks, administer a third dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for 4 weeks, administer a fourth dose of 9 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After the fourth dose is administered for 4 weeks, a fifth dose of 12 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks; preferably, a fifth dose of 12 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a fifth dose of 12 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks for more than 8 weeks; preferably, 12 mg of the compound of formula (I), or its pharmaceutically acceptable salt, amide or ester is administered once every two weeks for more than 28 weeks or more than 36 weeks.

21. The method according to any one of claims 1-6, 7-9 or 10-15, wherein: The method comprises administering to a subject in need thereof a first dose of 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for 4 weeks, administer a second dose of 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for 4 weeks, administer a third dose of 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After the third dose is administered for 4 weeks, a fourth dose of 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks; After administering the fourth dose for 4 weeks, administer a fifth dose of 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After the fifth dose is administered for 4 weeks, a sixth dose of 18 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks, preferably a sixth dose of 18 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably a sixth dose of 18 mg of the compound of formula (I) or its pharmaceutically acceptable salt, amide or ester is administered once a week or once every two weeks for 4 weeks. Weeks; preferably 18 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once every two weeks for 24 weeks or more or 32 weeks or more.

22. The method according to any one of claims 1-6, 7-9 or 10-15, wherein: The method comprises administering to a subject in need thereof a first dose of about 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for 4 weeks, administering a second dose of about 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for 4 weeks, administer a third dose of about 6 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the third dose for 4 weeks, administering a fourth dose of about 9 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the fourth dose for 4 weeks, administering a fifth dose of about 12 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After administering the fifth dose for 4 weeks, administering a sixth dose of about 18 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; After the sixth dose is administered for 4 weeks, a seventh dose of about 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; preferably, a seventh dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for more than 2 weeks, preferably more than 4 weeks, preferably more than 8 weeks, preferably more than 12 weeks, preferably more than 16 weeks, preferably more than 20 weeks; preferably, a seventh dose of 24 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks for 4 weeks.

23. The method according to any one of claims 1 to 6 or 7 to 9, wherein: The method comprises administering to a subject in need thereof a first dose of 0.5-1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or After administering the first dose for 1, 2, 3 or 4 weeks, administering a second dose of 1-3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or After administering the second dose for 2, 3, 4, 5, 6, 7, or 8 weeks, administering a third dose of 2-6 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or After administering the third dose for 2, 3, 4, 5, 6, 7, or 8 weeks, administering a fourth dose of 2.5-9 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; and / or After administering the fourth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, administering a fifth dose of 3-12 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or After administering the fifth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, administering a sixth dose of 3.5-18 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or After administering the sixth dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, administering a seventh dose of 4-24 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof once a week or once every two weeks; and / or After administering the seventh dose for 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 weeks, an eighth dose of 6-30 mg of a compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

24. The method according to any one of claims 1-6, 7-9 or 23, wherein: The first dose is 0.5-1.5 mg, preferably 0.5 mg, 0.6 mg, 1 mg, 1.2 mg, 1.5 mg, preferably 0.5 mg or 1.5 mg; and / or The second dose is 1-3 mg, preferably 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, preferably 1 mg or 3 mg; and / or The third dose is 2-6 mg, preferably 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, preferably 5 mg or 6 mg; and / or The fourth dose is 2.5-9 mg, preferably 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, preferably 2.5 mg, 7 mg or 9 mg; and / or The fifth dose is 3-12 mg, preferably 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, or 12 mg, preferably 3 mg, 9 mg or 12 mg; and / or The sixth dose is 3.5-18 mg, preferably 3.5 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, or 18 mg, preferably 3.5 mg, 11 mg, or 18 mg; and / or The seventh dose is 4-24 mg, preferably 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg or 24 mg, preferably 4 mg, 18 mg or 24 mg.

25. The method according to any one of claims 23-24, wherein: The method comprises administering to a subject in need thereof a first dose of 1.5 mg of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the first dose for 2 weeks, administer a second dose of 3 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After administering the second dose for 4 weeks, administer a third dose of 5 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, once a week or once every two weeks; After the third dose is administered for 4 weeks, a fourth dose of 7 mg of the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered once a week or once every two weeks; After the fourth dose is administered for 4 weeks, a fifth dose of 9 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; After the fifth dose is administered for 4 weeks, a sixth dose of 11 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks; and After the sixth dose is administered for 4 weeks, a seventh dose of 13 mg of the compound of formula (I) or a pharmaceutically acceptable salt, amide or ester thereof is administered once a week or once every two weeks.

26. The method according to any one of claims 1 to 25, characterized in that The compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered parenterally, preferably subcutaneously.

27. The method according to any one of claims 1 to 26, characterized in that The compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered for more than 12 months, preferably more than 16 months, preferably more than 18 months, preferably more than 24 months, preferably more than 28 months, preferably more than 29 months, preferably more than 30 months.

28. The method according to any one of claims 1 to 27, characterized in that The subject has a ≥18.5 kg / m 2 BMI, preferably 18.5-35 kg / m 2 BMI; and / or Have an HbA1c of 7.0%-11%; and / or Fasting blood glucose <15mmol / L.

29. The method according to any one of claims 1 to 28, wherein the compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof, is administered in the form of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients.

30. The method according to claim 29, wherein the pharmaceutical composition comprises: About 1.5 mg / ml, about 3 mg / ml, about 6 mg / ml, about 12 mg / ml, about 18 mg / ml, about 24 mg / ml, about 36 mg / ml, or about 48 mg / ml of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof; preferably about 3 mg / ml, about 6 mg / ml, about 12 mg / ml, about 18 mg / ml, about 24 mg / ml, about 36 mg / ml, or about 48 mg / ml of a compound of formula (I), or a pharmaceutically acceptable salt, amide or ester thereof salts, amides or esters; about 5 mg / ml, about 6 mg / ml, about 7 mg / ml, about 8 mg / ml, about 9 mg / ml or about 10 mg / ml of NaCl, preferably about 7 mg / ml of NaCl; About 1 mM, 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, 9 mM or about 10 mM citric acid; about 1.42 mg / ml, about 1.5 mg / ml, about 2 mg / ml, about 2.5 mg / ml, about 3 mg / ml, about 3.5 mg / ml, about 4 mg / ml, or about 4.5 mg / ml of a Na2HPO4 solution, preferably about 1.42 mg / ml of Na2HPO4; and The pH of the pharmaceutical composition is about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, about 8.0, about 8.1, or about 8.2, preferably about 7.3.